These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27181199)

  • 21. Titration of basal insulin or immediate addition of rapid acting insulin in patients not at target using basal insulin supported oral antidiabetic treatment - A prospective observational study in 2202 patients.
    Siegmund T; Pfohl M; Forst T; Pscherer S; Bramlage P; Foersch J; Borck A; Seufert J
    Diabetes Metab Syndr; 2017; 11(1):51-57. PubMed ID: 27578616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and Safety of Physician-Led Versus Patient-Led Titration of Insulin Glargine in Indian Patients with Type 2 Diabetes Mellitus: A Subanalysis of the Asian Treat to Target Lantus Study (ATLAS).
    Misra A; Patel M; Agarwal P; Lodha S; Tandon N; Magdum M; Yajnik C; Ghosh R; Walekar A
    Diabetes Technol Ther; 2019 Nov; 21(11):656-664. PubMed ID: 31335198
    [No Abstract]   [Full Text] [Related]  

  • 23. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insulin requirement profiles and related factors of insulin pump therapy in patients with type 2 diabetes.
    Yang X; Deng H; Zhang X; Yang D; Yan J; Yao B; Weng J; Xu W
    Sci China Life Sci; 2019 Nov; 62(11):1506-1513. PubMed ID: 31197759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naïve patients with type 2 diabetes.
    Oster G; Sullivan SD; Dalal MR; Kazemi MR; Rojeski M; Wysham CH; Sung J; Johnstone B; Cali AM; Wei LJ; Traylor L; Anhalt H; Hull M; Van Vleet J; Meneghini LF
    Postgrad Med; 2016 Nov; 128(8):731-739. PubMed ID: 27690710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
    Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
    Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P; Cooper J; Bregnhøj J; Pedersen CB
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world study on the effectiveness and safety of basal insulin IDegLira in type 2 diabetic patients previously treated with multi-injective insulin therapy.
    Persano M; Nollino L; Sambataro M; Rigato M; Negro I; Marchetto S; Paccagnella A
    Eur Rev Med Pharmacol Sci; 2021 Jan; 25(2):923-931. PubMed ID: 33577047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin Glargine U100 Improved Glycemic Control and Reduced Nocturnal Hypoglycemia in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3 and 4.
    Betônico CC; Titan SMO; Lira A; Pelaes TS; Correa-Giannella MLC; Nery M; Queiroz M
    Clin Ther; 2019 Oct; 41(10):2008-2020.e3. PubMed ID: 31383366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvement of glycemic control with addition of insulin detemir to existing antidiabetic therapy: a sub-group analysis of A1chieve observational study.
    Kesavadev J; Joshi SR
    J Assoc Physicians India; 2013 Jan; 61(1 Suppl):28-30. PubMed ID: 24482985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real-world setting.
    Meneghini LF; Mauricio D; Orsi E; Lalic NM; Cali AMG; Westerbacka J; Stella P; Candelas Dea C; Pilorget V; Perfetti R; Khunti K;
    Diabetes Obes Metab; 2019 Jun; 21(6):1429-1436. PubMed ID: 30768845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.
    Riddle M; Frias J; Zhang B; Maier H; Brown C; Lutz K; Kolterman O
    Diabetes Care; 2007 Nov; 30(11):2794-9. PubMed ID: 17698615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evaluation of the DIABOBHU Observational Study].
    Gaál Z; Papp Z; Bakó B
    Orv Hetil; 2014 Jun; 155(23):903-10. PubMed ID: 24880969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insulin pump therapy in patients with type 2 diabetes safely improved glycemic control using a simple insulin dosing regimen.
    Edelman SV; Bode BW; Bailey TS; Kipnes MS; Brunelle R; Chen X; Frias JP
    Diabetes Technol Ther; 2010 Aug; 12(8):627-33. PubMed ID: 20615104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
    Weng J
    J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
    Ligthelm RJ; Gylvin T; DeLuzio T; Raskin P
    Endocr Pract; 2011; 17(1):41-50. PubMed ID: 20713345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).
    Garber AJ; Wahlen J; Wahl T; Bressler P; Braceras R; Allen E; Jain R
    Diabetes Obes Metab; 2006 Jan; 8(1):58-66. PubMed ID: 16367883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period.
    Seino Y; Sasaki T; Fukatsu A; Imazeki H; Ochiai H; Sakai S
    Curr Med Res Opin; 2018 Jun; 34(6):981-994. PubMed ID: 29448833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy.
    Vinik A
    Clin Ther; 2007; 29 Spec No():1236-53. PubMed ID: 18046925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient characteristics and 6-month dose of basal insulin associated with HbA1c achievement <7.0% in Chinese people with type 2 diabetes: results from the Observational Registry of Basal Insulin Treatment (ORBIT).
    Gao L; Zhang P; Weng J; Lu J; Guo X; Jia W; Yang W; Zou D; Zhou Z; Pan C; Gao Y; Li X; Zhu D; Wu Y; Garg SK; Ji L
    J Diabetes; 2020 Sep; 12(9):668-676. PubMed ID: 32329194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.